查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997402

核子医学扫描术诊断设备市场：依产品、放射性药物、应用和最终用户划分－2026-2032年全球市场预测

Nuclear Imaging Equipment Market by Product, Radiopharmaceuticals, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核子医学扫描术诊断设备市场价值将达到 62.9 亿美元，到 2026 年将成长至 66.6 亿美元，到 2032 年将达到 95.5 亿美元，复合年增长率为 6.14%。

主要市场统计数据
基准年 2025 62.9亿美元
预计年份：2026年 66.6亿美元
预测年份 2032 95.5亿美元
复合年增长率 (%) 6.14%

本文简要概述了技术创新、营运压力和不断变化的临床需求如何重塑核子医学扫描术诊断设备的采用和普及。

核子医学扫描术诊断领域正处于变革的关键时期，技术创新、不断变化的临床需求和政策环境的交汇正在重塑诊断和治疗路径。检测器材料、重建演算法和混合成像架构的进步提高了核医学影像的敏感度和特异性，使临床医生能够更早发现病灶，并更深入地了解疾病的生物学特征。同时，放射性药物生产和分销网络的成熟扩大了可用示踪剂的范围，从而拓展了临床适应症，并推动了对特定成像方式设备的需求。

模态融合、放射性药物多样化和人工智慧驱动的分析如何从整体重新定义临床工作流程、经营模式和伙伴关係策略。

核子医学影像领域正经历一场变革，这场变革由三个相互关联的因素所驱动：影像方式的整合、放射性药物的多样化以及计算技术的进步。影像系统的混合化已不再局限于单一功能的升级，而是逐渐成为一项基本的架构原则。 PET/CT 和 SPECT/CT 整合平台能够实现解剖学和观察观察之间的无缝关联，从而提高诊断的准确性和检查效率。同时，放射性药物工具包也在不断扩展，纳入了高度标靶特异性的示踪剂和诊疗整合（治疗诊断）组合，将诊断与标靶治疗相结合。这正在改变影像中心和肿瘤诊所的临床路径和资金投入需求。

评估 2025 年实施的关税政策如何改变了核子医学扫描术诊断设备相关人员的供应链、采购行为和策略采购。

2025年实施的关税政策为核子医学扫描术诊断生态系统带来了新的成本和物流复​​杂性，其影响波及设备采购、备件库存以及放射性药物的整个供应链。进口影像组件和製造投入品关税的提高迫使供应商重新思考其全球采购策略，加速了关于近岸组装、供应商多元化以及重新谈判长期供应商合约的讨论。重要的是，这一趋势也影响临床医生的资本规划时间，许多医生现在开始将更长的前置作业时间週期和更高的总成本纳入设备升级和扩建的决策考虑。

透过细分市场洞察，揭示产品类型、放射性药物类别、临床应用和最终用户类型如何相互作用，从而确定采购优先顺序和营运权衡。

逐一细分市场分析市场动态，揭示了每种产品、示踪剂、临床环境和最终用户的独特实际情况，这些情况都会影响投资决策和营运设计。就产品架构而言，平面闪烁显像系统继续适用于较简单的诊断流程，而正子断层扫描 (PET) 扫描仪则提供高灵敏度的功能性影像，这对于先进的肿瘤学和神经学应用至关重要。单光子发射电脑断层扫描 (SPECT) 扫描仪则处于中间位置，混合型 SPECT 影像系统透过 CT 配抗蚀剂扩展了诊断功能，而独立式 SPECT 平台则为优先考虑处理能力的机构提供了经济高效的解决方案。这些产品差异决定了不同临床环境下的采购决策。

本研究从区域观点考察了美洲、欧洲、中东和非洲以及亚太地区的法规结构、还款趋势和製造地如何影响采用率和伙伴关係选择。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的应用曲线、监管复杂性和供应链选择，每个地区都有其独特的应用条件和策略机会。在美洲，成熟的报销框架和密集的转诊网路正在推动先进PET平台和混合系统的快速普及。同时，积极的临床研究正在加速新型示踪剂和治疗诊断学工作流程的早期应用。相较之下，一些公共医疗机构的资金限制正在推动开发资金筹措方案和管理服务协议，以降低初始成本，同时确保能够获得最先进的影像能力。

领先的供应商和服务供应商如何将与硬体、软体和放射性药物的伙伴关係整合起来，以创建稳健的、经常性的收入模式，并在竞争中脱颖而出？

核子医学扫描术诊断生态系统中的主要企业正在重新评估其策略，重点关注整合硬体、放射性药物利用和软体主导的临床工作流程的综合价值提案。供应商越来越重视可维护性和运作保证，因为他们认识到设备生命週期经济性和营运连续性对医院和诊断中心至关重要。与放射性药物製造商和物流供应商建立策略合作伙伴关係是确保端到端解决方案的关键，该解决方案将示踪剂供应和扫描仪部署连接起来，从而缩短患者等待时间并简化临床排班。

为医疗保健提供者、製造商和投资者制定可操作的策略重点，以增强供应链韧性、加快软体采用率，并将资本配置与临床价值连结起来。

产业领导者应优先采取三项策略行动，以平衡短期韧性与价值导向个人化医疗导向的长期定位。首先，实现采购多元化并加强与供应商的关係，以减轻关税造成的供应中断。这包括对关键零件进行选择性近岸外包，同时保持多个专业零件和耗材供应商。其次，加快软体和分析工具的投资，以提高扫描器的使用率和诊断处理能力。检验的人工智慧工具和定量报告系统可以显着降低营运成本并提升临床效果，从而支援差异化采购策略。

为了检验策略见解和假设，我们采用了严谨的混合方法研究途径，结合了专家访谈、医疗设备分析、监管审查和供应链映射。

本次高阶主管综合报告的基础研究采用跨学科方法，结合一手和二手研究，建构了可靠的证据基础。一手研究包括对临床终端使用者、采购经理和服务工程师进行结构化访谈，以了解营运限制、培训需求和运作优先事项。这些定性见解与设备规格、临床试验结果和监管核准趋势的技术分析相结合，以评估不同平台类型之间的功能差异。供应链图谱确定了组件和示踪剂分销的关键节点，情境分析则考察了政策变化和关税相关的成本波动敏感性。

整合的临床路径如何提供韧性，以及检验的软体解决方案如何发挥作用，将决定核子医学扫描术诊断设备市场的长期领导地位。

总而言之，核子医学扫描术诊断设备市场正从以设备为中心的市场向一体化的临床生态系统转变，放射性药物的供应、软体智慧和供应链韧性决定着其长期成功。混合成像和演算法重建技术的进步拓展了诊断能力，同时也提高了营运整合和临床检验的标准。关税带来的复杂情况给采购和物流带来了新的短期压力，但也促使企业进行策略调整，从长远来看，这些调整有望建立更具韧性的供应炼和本地化能力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章核子医学扫描术诊断设备市场：依产品分类

  • 平面闪烁成像系统
  • 正子断层扫描（PET）扫描仪
  • 单光子发射电脑断层扫描（SPECT）扫描仪
    • 混合SPECT影像系统
    • 独立式SPECT影像系统

第九章：核子医学扫描术诊断设备市场

  • 氟代脱氧葡萄糖（FDG）
  • 镓-68
  • 碘-131
  • Technetium-99m

第十章：核子医学扫描术诊断设备市场：依应用领域划分

  • 循环系统
  • 感染疾病诊断
  • 神经病学
  • 肿瘤学
  • 整形外科

第十一章核子医学扫描术诊断设备市场：依最终用户划分

  • 诊断影像中心
  • 医院和诊所
  • 研究机构

第十二章核子医学扫描术诊断设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章核子医学扫描术诊断设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章核子医学扫描术诊断设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国核子医学扫描术诊断设备市场

第十六章：中国核子医学扫描术诊断设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Absolute Imaging Inc.
  • Advanced Accelerator Applications SA by Norvatis
  • Agfa-Gevaert NV
  • Bayer AG
  • Bozlu Holding AS
  • Bracco Imaging SpA
  • Canon Medical Systems Corporation
  • CMR Naviscan Corporation
  • Cubresa Inc.
  • DDD-Diagnostic A/S
  • Digirad Corporation
  • Edge Medical Solutions Private Limited
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • MR Solutions Ltd.
  • Neusoft Medical Systems Co., Ltd.
  • PerkinElmer Inc.
  • Revvity Inc
  • Rigaku Corporation
  • Shimadzu Corporation
  • Siemens AG
  • Surgiceye GmbH
  • United Imaging Healthcare Co., Ltd.
Product Code: MRR-50124643717F

The Nuclear Imaging Equipment Market was valued at USD 6.29 billion in 2025 and is projected to grow to USD 6.66 billion in 2026, with a CAGR of 6.14%, reaching USD 9.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.29 billion
Estimated Year [2026] USD 6.66 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 6.14%

A concise framing of how technological innovation operational pressures and evolving clinical needs are reshaping nuclear imaging equipment deployment and adoption

The field of nuclear imaging equipment stands at an inflection point where technological innovation, evolving clinical needs, and shifting policy environments converge to reshape diagnostic and therapeutic pathways. Advances in detector materials, reconstruction algorithms, and hybrid imaging architectures have elevated both the sensitivity and specificity of nuclear scans, enabling clinicians to detect pathology earlier and to characterize disease biology with greater granularity. At the same time, the maturation of radiopharmaceutical manufacturing and distribution networks has expanded the portfolio of available tracers, which in turn broadens clinical indications and drives demand for modality-specific instrumentation.

Despite these technical gains, stakeholders face increasing complexity in procurement decisions, operational workflows, and capital allocation. Imaging service providers must balance investments in cutting-edge PET and SPECT platforms against the realities of staffing, reagent availability, and reimbursement frameworks. Consequentially, leaders across clinical, operational, and commercial functions require evidence-based intelligence that links device capability to clinical impact and operational feasibility. This executive summary synthesizes those dynamics, highlighting structural shifts, regulatory and trade influences, segmentation-level insights, regional considerations, and practical recommendations that equip decision-makers to navigate the near-term landscape with clarity and confidence.

How modality convergence radiopharmaceutical diversification and AI-driven analytics are collectively redefining clinical workflows commercial models and partnership strategies

The nuclear imaging landscape is undergoing transformative shifts driven by three interrelated vectors: modality convergence, radiopharmaceutical diversification, and computational augmentation. Hybridization of imaging systems has moved beyond single-point upgrades to become a dominant architectural principle, with integrated PET/CT and SPECT/CT platforms enabling seamless anatomical-functional correlation that improves diagnostic confidence and procedural efficiency. Concurrently, the radiopharmaceutical toolkit has expanded to incorporate tracers with higher target specificity and theranostic pairings that link diagnosis to targeted therapy, thereby altering clinical pathways and capital requirements for imaging centers and oncology clinics.

Complementing hardware and tracer innovation, advances in artificial intelligence and quantitative analytics are changing how images are reconstructed, interpreted, and integrated into clinical decision-making. Machine learning-driven denoising and lesion detection improve effective throughput and reduce repeat scans, while standardized quantitative metrics enhance longitudinal patient monitoring. Regulatory agencies are increasingly defining pathways for software-as-a-medical-device approvals, prompting vendors to reorient product roadmaps toward validated algorithmic components. Moreover, supply chain resiliency and localized manufacturing initiatives are shifting procurement behavior, encouraging strategic partnerships between equipment manufacturers, radiopharmaceutical producers, and service organizations. Taken together, these shifts create a landscape in which clinical value, workflow integration, and ecosystem partnerships determine long-term leadership rather than device specifications alone.

Assessment of how tariff policy enacted in 2025 has altered supply chains procurement behavior and strategic sourcing among nuclear imaging equipment stakeholders

Tariff policy implemented in 2025 introduced a new layer of cost and logistical complexity for the nuclear imaging ecosystem, with ramifications reverberating across device procurement, spare-parts inventory, and radiopharmaceutical supply chains. Increased duties on imported imaging components and manufacturing inputs have pressured vendors to reassess global sourcing footprints, accelerating conversations about nearshoring assembly, diversifying supplier bases, and renegotiating long-term supplier agreements. Importantly, this dynamic has also influenced capital planning horizons for clinical providers, many of whom are now factoring extended lead times and higher landed costs into replacement and expansion decisions.

Beyond hardware, tariffs have affected the movement of radiopharmaceutical-related consumables and specialized hardware modules, prompting some suppliers to consolidate logistics and to pursue simplified product configurations that reduce dependency on tariffed components. In response, purchasers have adopted a mix of mitigation strategies including expanded service contracts to preserve uptime, selective inventory buffers for critical spare parts, and greater use of multi-year procurement agreements to lock in pricing predictability. Policy-driven cost inflation has also accelerated demand for value-based procurement models, wherein equipment selection criteria emphasize throughput, reagent efficiency, and serviceability over headline specifications. While tariffs introduce short-term cost pressures, they have also catalyzed structural shifts that may improve long-term supply resilience through localized supply networks and strategic vendor partnerships.

Segment-aware intelligence revealing how product categories radiopharmaceutical classes clinical applications and end-user types jointly determine procurement priorities and operational trade-offs

Segment-focused interpretation of market dynamics reveals distinct product, tracer, clinical, and end-user realities that influence investment decisions and operational design. Within product architecture, planar scintigraphy imaging systems continue to serve lower-complexity diagnostic workflows, while positron emission tomography scanners deliver high-sensitivity functional imaging essential for advanced oncology and neurology applications. Single Photon Emission Computed Tomography scanners occupy a middle ground where hybrid SPECT imaging systems extend diagnostic capability through CT co-registration and stand-alone SPECT platforms offer cost-effective solutions for centers prioritizing throughput. These product distinctions drive procurement logic across diverse clinical settings.

Radiopharmaceutical availability and characteristics exert a parallel influence. Fluorodeoxyglucose remains a central workhorse tracer for metabolic imaging, whereas Gallium-68's utility in peptide receptor imaging and novel theranostic applications has increased clinical demand for on-site or regional generator solutions. Iodine-131 retains relevance for established therapeutic indications, and Technetium-99m continues to underpin a broad array of routine scintigraphic studies due to its favorable physical properties and wide distribution infrastructure. Clinically, cardiology and oncology dominate utilization patterns for high-end modalities, with neurology and infectious disease diagnosis requiring specialized tracers and protocols. Orthopedics relies more on planar and SPECT techniques for targeted evaluations. End-user distinctions matter: diagnostic imaging centers prioritize throughput and multi-modality capability to serve referral networks, hospitals and clinics require integration with broader electronic medical records and interventional suites, and research institutes demand flexible platforms that support investigational tracers and rapid protocol changes. Aligning product selection with tracer strategy, clinical indication, and end-user operational constraints is essential to optimize returns on capital and clinical impact.

A regional lens on how regulatory frameworks reimbursement dynamics and manufacturing footprints across Americas EMEA and Asia-Pacific drive differentiated adoption and partnership choices

Regional dynamics shape adoption curves, regulatory complexity, and supply-chain choices across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each geography presenting unique deployment conditions and strategic opportunities. In the Americas, mature reimbursement frameworks and high-density referral networks favor rapid uptake of advanced PET platforms and hybrid systems, while strong clinical research activity drives early adoption of novel tracers and theranostic workflows. Conversely, capital constraints at some public facilities encourage financing options and managed service agreements that reduce upfront expenditure while preserving access to modern imaging capability.

Europe, Middle East & Africa present a heterogeneous set of regulatory and reimbursement environments where centralized health technology assessment processes in some jurisdictions drive rigorous value demonstration, and in others, emerging markets exhibit demand for cost-efficient SPECT and planar systems. The region's diversity also creates opportunities for platform standardization that supports multinational clinical trials and cross-border service models. In the Asia-Pacific region, rapid expansion of diagnostic infrastructure, investments in local radiopharmaceutical production, and strong government interest in domestic manufacturing have accelerated deployment of both PET and SPECT systems. These markets are characterized by a combination of high-volume clinical demand and an appetite for integrated service models, including remote monitoring and AI-enabled workflow optimization. Across regions, regulatory pathways for software and radiopharmaceutical approval, reimbursement policy shifts, and local manufacturing capabilities will continue to drive differentiated adoption patterns and partnership models.

How major vendors and service providers are integrating hardware software and radiopharmaceutical partnerships to create resilient recurring-revenue models and competitive differentiation

Leading organizations in the nuclear imaging equipment ecosystem are realigning strategies around integrated value propositions that combine hardware, radiopharmaceutical enablement, and software-driven clinical workflows. Vendors are placing greater emphasis on serviceability and uptime guarantees, recognizing that equipment lifecycle economics and operational continuity are decisive factors for hospitals and diagnostic centers. Strategic alliances with radiopharmaceutical manufacturers and logistics providers have become frontline tactics to secure end-to-end solutions that link tracer availability with scanner deployment, thereby reducing patient wait times and simplifying clinical scheduling.

In parallel, a cohort of companies is investing heavily in scalable software platforms to deliver quantitative imaging, decision support, and remote monitoring services. These offerings are designed to create sticky revenue streams and to enable performance-based contracts tied to throughput, diagnostic accuracy, or treatment planning efficacy. Companies are also experimenting with flexible commercial models including pay-per-scan arrangements and subscription-based access to premium analytics, which appeal to resource-constrained buyers. Finally, successful players prioritize regulatory strategy and clinical evidence generation, partnering with academic centers to validate new tracers, reconstruction algorithms, and theranostic pathways that support differentiated value propositions in competitive procurement processes.

Actionable strategic priorities for providers manufacturers and investors to enhance supply resilience accelerate software adoption and link capital deployment to clinical value

Industry leaders should prioritize a triage of strategic actions that balance near-term resilience with long-term positioning for value-based, personalized care. First, diversify sourcing and strengthen supplier relationships to mitigate tariff-induced supply disruptions; engage in selective nearshoring for critical components while maintaining multi-sourced options for specialized parts and consumables. Second, accelerate investments in software and analytics that improve scanner utilization and diagnostic throughput; validated AI tools and quantitative reporting systems can materially reduce operational costs and improve clinical impact, thereby supporting differentiated procurement justifications.

Third, cultivate strategic partnerships with radiopharmaceutical manufacturers and logistics providers to ensure tracer availability aligns with clinical schedules and to enable integrated service offerings. Fourth, adopt flexible commercial models that reduce capital barriers for buyers, such as managed service contracts, outcome-linked pricing, and modular upgrade paths that extend device lifecycles. Fifth, engage proactively with regulators and payers through robust evidence generation and health economic demonstration projects to secure favorable reimbursement and to streamline approvals for software-enabled features. Collectively, these actions will support sustainable growth while improving access to advanced diagnostic and theranostic workflows for diverse care settings.

A rigorous mixed-methods research approach combining expert interviews device analytics regulatory review and supply-chain mapping to validate strategic insights and assumptions

The research underpinning this executive synthesis combined a multidisciplinary approach incorporating primary and secondary inputs to create a robust evidence base. Primary research included structured interviews with clinical end-users, procurement leaders, and service engineers to capture operational constraints, training needs, and uptime priorities. These qualitative insights were triangulated with technical analyses of device specifications, clinical trial outcomes, and regulatory approval trends to assess capability differentials among platform types. Supply chain mapping identified critical nodes for components and tracer distribution, while scenario analysis explored sensitivity to policy shifts and tariff-related cost movements.

Secondary research drew on peer-reviewed clinical literature, regulatory filings, patent databases, and public disclosures from manufacturers and healthcare providers to validate assertions regarding technology performance and clinical utility. Where applicable, clinical guideline updates and published comparative effectiveness studies informed assessments of tracer-specific value propositions. Throughout the research process, methodological rigor was maintained through iterative validation with subject-matter experts and by documenting data provenance and analytical assumptions. The outcome is a synthesized perspective designed to inform strategic decision-making without relying on proprietary or proprietary forecasting outputs.

Synthesis of how integrated clinical pathways supply resilience and validated software offerings will determine long-term leadership in nuclear imaging equipment markets

In summary, the nuclear imaging equipment landscape is evolving from a device-centric market into an integrated clinical ecosystem where radiopharmaceutical availability, software intelligence, and supply-chain resilience determine long-term success. Technological advances in hybrid imaging and algorithmic reconstruction have expanded diagnostic capability while also raising the bar for operational integration and clinical validation. Tariff-driven complexities introduced new short-term pressures on procurement and logistics, but they also incentivized strategic adjustments that may yield more resilient supply architectures and localized capability over time.

Decision-makers should therefore align investment choices with clinical use cases, operational constraints, and regional regulatory realities. By privileging solutions that combine diagnostic accuracy, workflow efficiency, and service robustness, providers can deliver improved patient outcomes while containing total cost of ownership. Manufacturers and investors that focus on integrated offerings, flexible commercial arrangements, and validated software components will be positioned to capture enduring value as care pathways increasingly depend on precise molecular imaging and theranostic alignment. The path forward requires collaborative ecosystems, evidence-driven product design, and pragmatic commercial models that translate technological promise into measurable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Imaging Equipment Market, by Product

  • 8.1. Planar Scintigraphy Imaging Systems
  • 8.2. Positron Emission Tomography (PET) Scanners
  • 8.3. Single Photon Emission Computed Tomography (SPECT) Scanners
    • 8.3.1. Hybrid SPECT Imaging Systems
    • 8.3.2. Standalone SPECT Imaging Systems

9. Nuclear Imaging Equipment Market, by Radiopharmaceuticals

  • 9.1. Fluorodeoxyglucose (FDG)
  • 9.2. Gallium-68
  • 9.3. Iodine-131
  • 9.4. Technetium-99m

10. Nuclear Imaging Equipment Market, by Application

  • 10.1. Cardiology
  • 10.2. Infectious Disease Diagnosis
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Nuclear Imaging Equipment Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Nuclear Imaging Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Imaging Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Imaging Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nuclear Imaging Equipment Market

16. China Nuclear Imaging Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Absolute Imaging Inc.
  • 17.6. Advanced Accelerator Applications S.A. by Norvatis
  • 17.7. Agfa-Gevaert N.V
  • 17.8. Bayer AG
  • 17.9. Bozlu Holding A. S.
  • 17.10. Bracco Imaging S.p.A.
  • 17.11. Canon Medical Systems Corporation
  • 17.12. CMR Naviscan Corporation
  • 17.13. Cubresa Inc.
  • 17.14. DDD-Diagnostic A/S
  • 17.15. Digirad Corporation
  • 17.16. Edge Medical Solutions Private Limited
  • 17.17. GE HealthCare Technologies Inc.
  • 17.18. Koninklijke Philips N.V.
  • 17.19. Mediso Ltd.
  • 17.20. MR Solutions Ltd.
  • 17.21. Neusoft Medical Systems Co., Ltd.
  • 17.22. PerkinElmer Inc.
  • 17.23. Revvity Inc
  • 17.24. Rigaku Corporation
  • 17.25. Shimadzu Corporation
  • 17.26. Siemens AG
  • 17.27. Surgiceye GmbH
  • 17.28. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 135. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)